Fingerprint
Dive into the research topics of 'Commentary on a phase III trial of Bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: The NO16966 trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically